CoChat

Antibiotic Usage Reduced Overall Survival by over 70% in Non-small Cell Lung Cancer Patients on Anti-PD-1 Immunotherapy

Open access
HAMADA, KAZUYUKI, YOSHIMURA, KIYOSHI, HIRASAWA, YUYA, HOSONUMA, MASAHIRO, MURAYAMA, MASAKAZU, NARIKAWA, YOICHIRO, ARIIZUMI, HIROTSUGU, OHKUMA, RYOTARO, SHIDA, MIDORI, KUBOTA, YUTARO, MATSUKUMA, SATOSHI, ISHIGURO, TOMOYUKI, SAMBE, TAKEHIKO, HORIIKE, ATSUSHI, KURAMASU, ATSUO, WADA, SATOSHI, TSURUTANI, JUNJI, INOUE, EISUKE, UCHIDA, NAOKI, KIUCHI, YUJI, KOBAYASHI, SHINICHI, HOFFMAN, ROBERT M., TSUNODA, TAKUYA · 2021 · Anticancer Research
Cited by 43

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

BACKGROUND/AIM: There is an increasing use of immunotherapy for non-small cell lung cancer (NSCLC) patients. The present study analysed the effect of antibiotic use on the outcome of NSCLC patients undergoing treatment with anti-programmed cell death-1 (anti-PD-1) immunotherapy. PATIENTS AND METHODS: This was a retrospective study of 69 NSCLC patients. Eighteen out of 69 patients received antibiotics within 21 days before or within 21 days after start of anti-PD-1 therapy. RESULTS: Patients treated with anti-PD-1 antibodies receiving antibiotics had greatly decreased objective response rate (ORR), overall survival (OS) and progression-free survival (PFS) compared to those who did not use antibiotics. Multivariate analysis showed that antibiotic treatment of patients on anti-PD-1 antibody therapy was an independent negative predictive factor of PFS; however, it was not a significant independent predictive factor of OS. CONCLUSION: Use of antibiotics within 21 days before and after anti-PD-1 treatment initiation in patients with NSCLC strongly reduced OS and PFS, suggesting the two treatments should not be combined.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.21873/anticanres.15312

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 43

Metadata

Authors
HAMADA, K., YOSHIMURA, K., HIRASAWA, Y., HOSONUMA, M., MURAYAMA, M., NARIKAWA, Y., ARIIZUMI, H., OHKUMA, R., SHIDA, M., KUBOTA, Y., MATSUKUMA, S., ISHIGURO, T., SAMBE, T., HORIIKE, A., KURAMASU, A., WADA, S., TSURUTANI, J., INOUE, E., UCHIDA, N., KIUCHI, Y., KOBAYASHI, S., HOFFMAN, R. M., & TSUNODA, T.
Venue
Anticancer Research
Published
2021-09-30
Volume
41
Issue
10
Pages
4985-4993
ISSN
  • 0250-7005 (ISSN-L)
  • 1791-7530
OpenAlex
W3204478304
Cited by
43
References
12
FWCI
2.12
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Antibiotic Usage Reduced Overall Survival by over 70% in Non-small Cell Lung Cancer Patients on Anti-PD-1 Immunotherapy. https://app.cochat.ai/papers/10.21873/anticanres.15312
The paper
HAMADA, K., YOSHIMURA, K., HIRASAWA, Y., HOSONUMA, M., MURAYAMA, M., NARIKAWA, Y., ARIIZUMI, H., OHKUMA, R., SHIDA, M., KUBOTA, Y., MATSUKUMA, S., ISHIGURO, T., SAMBE, T., HORIIKE, A., KURAMASU, A., WADA, S., TSURUTANI, J., INOUE, E., UCHIDA, N., . . . TSUNODA, T. (2021). Antibiotic Usage Reduced Overall Survival by over 70% in Non-small Cell Lung Cancer Patients on Anti-PD-1 Immunotherapy. Anticancer Research. https://doi.org/10.21873/anticanres.15312

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.